Internal Reference Number: FOI_8329
Date Request Received: 05/12/2024 00:00:00
Date Request Replied To: 07/01/2025 00:00:00
This response was sent via: By Email
Request Summary: Atopic Dermatitis
Request Category: Researcher
| Question Number 1: How many patients were treated in the last 4 months (August to November 2024) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Lebrikizumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only • Tacrolimus ointment • Tralokinumab • Upadacitinib • Nemolizumab | |
| Answer To Question 1: • Abrocitinib <5 • Acitretin 13 • Alitretinoin <5 • Azathioprine <5 • Baricitinib 0 • Ciclosporin 14 • Dupilumab 27 • Lebrikizumab <5 • Methotrexate 27 • Mycophenolate mofetil <5 • Pimecrolimus <5 • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only - <5 • Tacrolimus ointment 21 • Tralokinumab <5 • Upadacitinib <5 • Nemolizumab 0 | |
| Question Number 2: If possible, for the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • 6 months to 5 • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 2: Phototherapy (UVB or PUVA) - for Atopic Dermatitis only - all aged 18 and above, for all other treatments: • 6 months to 5 = 6 • Age 6-11 = 0 • Age 12-17 = <5 • Age 18 and above = 103 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
